2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2352

Real-World Distribution of Anti-Cyclic Citrullinated Peptide Concentrations and Impact on Treatment Patterns of Patients with Rheumatoid Arthritis
Abstract Number: 244

Real-World Evidence Associated with the Treatment of Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
Abstract Number: 419

Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study
Abstract Number: 204

Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US
Abstract Number: 1374

Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Abstract Number: 1205

Real-World Remission Outcomes in the First Year Following RA Diagnosis Vary Considerably with the Disease Activity Index Used and a Sizable Proportion Have Persistent Active Disease Across All Measures: Results from the Canadian Early Arthritis Cohort (CATCH)
Abstract Number: 2444

Real-world Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Biologic Therapies
Abstract Number: 1481

Real-World Use of Apremilast in Combination with Biologic Therapy in Patients with Psoriatic Arthritis: Findings from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Abstract Number: 2698

Reasons for Initiation of Canakinumab of Patients with Systemic Juvenile Idiopathic Arthritis: A Retrospective Medical Chart Review from the United States
Abstract Number: 203

Recent Use, Missed Doses and Discontinuation of Infliximab in a Population-Based Cohort: Comparisons of Biosimilar and Originator Exposures
Abstract Number: PP04

Reclaiming Medical Autonomy Through Healthcare Advocacy
Abstract Number: 631

Recognition of Inflammatory Back Pain by US Healthcare Providers and Barriers to Specialist Referral
Abstract Number: 1257

Recommendation on Colchicine Dosing and Definition of Colchicine Resistance/Intolerance in the Management of Familial Mediterranean Fever
Abstract Number: 2485

Red Cell Distribution Width Positively Correlates with Atherosclerotic Cardiovascular Disease Risk Score in Psoriatic Arthritis and Decreases with BDMARD Therapy
Abstract Number: 736

Reduced Circulating Levels of Inorganic Pyrophosphate Are Associated with Ectopic Calcification in Scleroderma Spectrum Disorders

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].